| DC66645 |
Epilactose
Featured
|
|
|
| DC66646 |
Dinotefuran UF
Featured
|
Dinotefuran UF is the deuterium labeled γ-Tocotrienol. γ-Tocotrienol is an active form of vitamin E |
|
| DC66647 |
ICA-1S
Featured
|
ICA-1S is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι), does not inhibit PKC-ζ, the closely related atypical PKC family member. |
|
| DC60638 |
Acid-degradable PEG Lipid (ADP-2k)
Featured
|
Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
|
| DC60639 |
Acid-degradable Anionic Lipid (ADA)
Featured
|
ADA (Acid-Degradable Anionic Lipids) is revolutionizing mRNA delivery with its unique azido-acetal linker, enabling rapid hydrolysis in endosomes (pH ~6.0). This breakthrough technology ensures efficient endosomal escape, significantly enhancing mRNA delivery to target cells. ADA-LNPs excel in delivering mRNA to the spleen and liver, making them ideal for immune-related therapies.By degrading into biocompatible byproducts, ADA minimizes long-term tissue persistence and toxicity.ADA-LNPs outperform traditional LNPs, delivering mRNA more effectively to immune cells like macrophages and B cells. |
.png)
|
| DC60640 |
LI-3948
Featured
|
LI-3948 is a blood-brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor with IC50 of 16 nM and brain/plasma ratio of 1.3, respectively. |
|
| DC66648 |
CP-LC-1143
Featured
|
Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
|
| A073 |
Antitope patent anti-CTLA4 Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody)
Featured
|
|
|
| A074 |
Tremelimumab Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody)
Featured
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research. |
.png)
|
| A075 |
Vunakizumab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody)
Featured
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. |
.png)
|
| A076 |
Perakizumab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody)
Featured
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis. |
.png)
|
| A077 |
Netakimab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody)
Featured
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. |
.png)
|
| A078 |
Med. Bio. Labs patent anti-CXADR Biosimilar (Anti-CXADR Reference Antibody)
Featured
|
|
|
| A079 |
Genentech patent anti-IL-8 Biosimilar (Anti-CXCL8 / IL-8 Reference Antibody)
Featured
|
|
|
| A080 |
Roche patent anti-CCN1 Biosimilar (Anti-CYR61 / CCN1 Reference Antibody)
Featured
|
|
|
| A081 |
Dragonfly patent anti-DLL3 Biosimilar （Anti-DLL3 Reference Antibody）
Featured
|
|
|
| A082 |
Begelomab Biosimilar （Anti-DPP4 / CD26 Reference Antibody）
Featured
|
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. |
.png)
|
| A083 |
Citatuzumab Biosimilar（Anti-EpCAM / TROP1 / CD326 Reference Antibody）
Featured
|
|
|
| A084 |
MEDI-547 Biosimilar（Anti-EphA2 Reference Antibody）
Featured
|
|
|
| A085 |
Sanofi Aventis patent anti-EphA2 Biosimilar（Anti-EphA2 Reference Antibody）
Featured
|
|
|
| A086 |
Disitamab Biosimilar（Anti-ERBB2 / HER2 / CD340 Reference Antibody）
Featured
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)). |
.png)
|
| A087 |
Tisotumab Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody）
Featured
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. |
.png)
|
| A088 |
TNX-832 Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody ）
Featured
|
|
|
| A089 |
Novo Nordisk patent anti-Factor VIII Biosimilar（Anti-F8 / Factor VIII Reference Antibody）
Featured
|
|
|
| A090 |
Emicizumab Biosimilar（Anti-F9 / Factor IX Reference Antibody）
Featured
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. |
|
| A091 |
Sibrotuzumab Biosimilar（Anti-FAP Reference Antibody）
Featured
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). |
.png)
|
| A092 |
VIB9600 Biosimilar(Anti-FcgR2a / CD32a Reference Antibody)
Featured
|
|
|
| A093 |
Cevostamab Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody)
Featured
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. |
.png)
|
| A094 |
DFRF4539A Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody)
Featured
|
|
|
| A095 |
Rozanolixizumab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. |
.png)
|
